Looking to expand your partner network with leading companies like LIfT BioSciences? Consider joining Inpart's global network for free.
News and Trends 6 Jul 2023
LIfT produces neutrophil-based cell therapy from iPSCs
LIfT BioSciences has announced successful proof-of-concept production of its patented cancer-killing alpha neutrophils from induced pluripotent stem cells (iPSCs). The proof-of-concept using iN-LIfT, the company’s second-generation platform, which is derived from iPSCs (a type of cell that has been reprogrammed so it is capable of becoming any type of cell) has shown that the alpha […]
